Fabry disease is a rare, X-linked lysosomal storage disorder that results in deficient or absent α-galactosidase and lysosomal accumulation of globotriaosylceramide and related glycosphingolipids across a wide variety of cells and tissues.

Participants of this activity will gain understanding of DOACs, the risk of bleeding with DOACs, the differences and similarities of available novel reversal agents, and most importantly, practical strategies for implementing these agents into the critical care setting.

Explain the role of non-statin therapies in cardiovascular risk management. Summarize the mechanism of action, efficacy, and safety of novel agents for LDL-C and ASCVD risk reduction

Type 1 diabetes (T1D) has an extensive global presence and affects over 1.25 million Americans who live with the daily challenges of appropriate insulin dosing and glucose monitoring.

This activity will help clinicians apply a guideline-based approach for management of acute and chronic pain as well as the complications of SCD.

Characterize current intraocular agents used to treat glaucoma according to efficacy, safety, and preservative content

Evaluate the latest safety and efficacy data for each approved GLP-1 RA Incorporate GLP-1 RAs into effective T2DM treatment plans based on the latest expert and guideline recommendations.

COVID-19 news is changing rapidly and we are all trying to stay on top of the latest medical information from trusted sources. Join Dr. Paul Auwaerter from Johns Hopkins School of Medicine and the former president of the Infectious Diseases Society of America for a free CME webinar covering what we know about the coronavirus outbreak.